The Centers for Disease Control and Prevention (CDC) report states that around 400 babies in the U.S. are born with hemophilia A. Further, it also highlights that approximately 33000 of male population in the U.S. is dealing with the health condition. This scenario highlights that there is noteworthy rise in the number of patients dealing with the hemophilia health condition across the major part of the globe. This is one of the key factors generating prominent sales opportunities for players in the global hemophilia treatment drugs market in the forecast period 2018–2026, opines a new research report published by TMR.
Hemophilia refers to a bleeding health condition in which an individual’s blood clotting process is damaged due to which they may face many issues including spontaneous bleeding and others. The occurrence of this disease is more common among male population from all across the globe. The treatment options available for this health condition are generally termed as hemophilia treatment drugs.
Growing Interest of Government Bodies to Offer Superior Health Care to Hemophilia Patients Creates Substantial Avenues for Market Expansion
The government bodies of many countries across the globe are focused on providing superior health services to the hemophilia patients. To accomplish their motive, several government authorities are accelerating their drugs approvals processes. This factor is likely to bring extensive expansion opportunities in the hemophilia market in the forthcoming years.
Shire Plc: Prominent Player Holding Key Share of Hemophilia Treatment Drugs Market
CSL Behring, Pfizer, Inc., Kedrion, Shire plc, Novo Nordisk A/S, Bayer AG, Sanofi, and F. Hoffmann-La Roche Ltd. are some of the key companies operating in the global hemophilia treatment drugs market. The presence of many well-entrenched players shows that the competitive landscape of the market is highly intense. Among all players, Shire plc held prominent market share in 2017. Sturdy product portfolio, wide regional presence, and involvement in acquisition activities are some of the key tactics that helped the organization to gain the leading position in the global hemophilia treatment drugs market.
Major players in the global hemophilia treatment drugs market are focused on the research and development activities. The tactic is helping them in the development of advanced treatment solutions on hemophilia. Apart from this, many enterprises in the hemophilia treatment drugs market are participating in acquisition, partnership, and collaboration activities. These strategies are helping them in expanding their businesses in the global hemophilia treatment drugs market.
Europe and North America: Prominent Regions of Hemophilia Treatment Drugs Market
Latin America, Europe, North America, Middle East & Africa, and Asia Pacific are some of the key regions for the hemophilia treatment drugs market. Of them, North America and Europe are major regions of the market. These regions are projected to maintain their prominent position in hemophilia treatment drugs market in the forecast period 2018–2026. Some of the key factors supporting this projection include growth in the health care budgets by regional government bodies, increased efforts of government bodies for growing awareness regarding the availability of varied advanced hemophilia treatment solutions, and high immigration rate from the tropical regions.
Global Hemophilia Treatment Drugs Market Segmentation
The global hemophilia treatment drugs market is segmented based on different crucial aspects such as product type, distribution channel, disease indication, and region. Based on product type, the market for hemophilia treatment drugs is divided into two parts, namely, plasma-derived coagulation factor concentrates and recombinant coagulation factor concentrates. In terms of distribution channel, the market is classified into online pharmacies, retail pharmacies, and hospital pharmacies. On the basis of disease indication, the classification of the hemophilia treatment drugs market is performed into three important parts, namely, hemophilia A, hemophilia B, and others.
The study presented here is based on a report by Transparency Market Research (TMR) titled “Hemophilia Treatment Drugs Market (Product Type - Recombinant Coagulation Factor Concentrates, Plasma derived Coagulation Factor Concentrates; Disease Indication - Hemophilia A, Hemophilia B, Others; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026.”
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information, we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.”
Transparency Market Research
90 State Street,
Albany NY - 12207
USA - Canada Toll Free: 866-552-3453